Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
List of authors.
Jason D. Goldman, M.D., M.P.H., David C.B. Lye, M.B., B.S., David S. Hui, M.D., Kristen M. Marks, M.D., Raffaele Bruno, M.D., Rocio Montejano, M.D., Abstract BACKGROUND
Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).
METHODS
We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale.
RESULTS
In total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P=0.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P=0.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%).
CONCLUSIONS
In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899. opens in new tab.)
各位还是应该对网友有基本的信任。
尽管她后来写的医院故事我没有读，不知道具体说了什么故无法评论。但她开始几篇肯定是真的，从她妈发烧开始她来健康坛求教，求法求祈祷那种焦虑绝对不可能是编出来的，而且她妈的病情是一点点的在变坏，程度与时间上都非常合情合理。你这样说她我不得不说你不厚道！！鄙视你们！
记忆里在这个坛大家都关心她妈的康复进展，都是祝福什么的。
https://www.nejm.org/doi/full/10.1056/NEJMoa2015301
方法
我们进行了一项随机，开放标签的3期临床试验，涉及住院患者的确诊SARS-CoV-2感染，呼吸环境空气时氧饱和度不超过94％以及肺炎的放射学证据。患者按1：1比例随机分配，接受5天或10天静脉注射雷姆昔韦。所有患者均在第1天接受200 mg瑞地昔韦，随后几天每天接受100 mg一次。主要终点为第14天的临床状态，按7点顺序量表进行评估。
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19List of authors.
Jason D. Goldman, M.D., M.P.H., David C.B. Lye, M.B., B.S., David S. Hui, M.D., Kristen M. Marks, M.D., Raffaele Bruno, M.D., Rocio Montejano, M.D., Abstract BACKGROUNDRemdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).
METHODSWe conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale.
RESULTSIn total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P=0.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P=0.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%).
CONCLUSIONSIn patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899. opens in new tab.)
还嫌网友被伤的不够，挖出旧贴来到底想干吗？
真是佩服这没完没了翻旧账能耐，有这闲工夫干点正事吧。。
讲补中益气与新冠病
https://blog.wenxuecity.com/myblog/73054/202005/34707.html
刚得过新冠的，应该仔细看看。
我以前也聊过，在政府部门拿年薪的，有些行业部门也给加班费，算出你一小时应该是多少钱给你，有人就顶我，说拿年薪在政府部门和公司都没加班费的，说我没工作的人想当然瞎说，我都懒着駁了，我看到的都是实例，但不想再细说了。